PD Dr. Dietrich A. Rueß

Further involvements

• Th, 15/02

  16:40 – 16:45 3 Min. 2 Min.

  • ePoster presentation
  • P20

  Mechanisms of resistance to targeted SHP2-inhibition +/- MAPK- or KRAS^G12D-inhibition in pancreatic cancer

   Pancreatic cancer
• Th, 15/02

  18:10 – 18:20 8 Min. 2 Min.

  • Oral presentation
  • O17

  Tumor-immune-microenvironmental implications of targeted SHP2-inhibition +/- MAPK-inhibition in pancreatic cancer

   Pancreatic cancer
• Fr, 16/02

  18:05 – 18:15 8 Min. 2 Min.

  • Oral presentation
  • O40

  DRACULA – drainage and flushing therapy in necrotizing pancreatitis; a retrospective, multicentric study

   Acute/chronic pancreatitis
• Sa, 17/02

  10:50 – 10:55 3 Min. 2 Min.

  • ePoster presentation
  • P54

  Impact of targeted SHP2-inhibition +/- MAPK-Inhibition on metabolic rewiring in pancreatic cancer

   Pancreatic cancer
• Sa, 17/02

  11:50 – 11:55 3 Min. 2 Min.

  • ePoster presentation
  • P75

  Implications of targeted SHP2-inhibition +/- MAPK-inhibition on cancer-associated fibroblasts in pancreatic cancer

   Tumour microenvironment, epigenetics and stem cells